{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:07:49Z","timestamp":1789578469735,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.mayocp.2022.09.007","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T11:33:10Z","timestamp":1675251190000},"page":"301-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review"],"prefix":"10.1016","volume":"98","author":[{"given":"Matthew","family":"Mintz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Barjaktarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-8745","authenticated-orcid":false,"given":"Barry","family":"Make","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Skolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Yawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bree","family":"Zeyzus-Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mayocp.2022.09.007_bib1","article-title":"Global and regional estimates of COPD prevalence: systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J\u00a0Glob Health"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-020-1291-8","article-title":"Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017","volume":"21","author":"Xie","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.mayocp.2022.09.007_bib3","doi-asserted-by":"crossref","unstructured":"Ahmad FB, Cisewski JA, Minino A, Anderson RN. Provisional mortality data\u2014United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(14):519-522. Published correction appears in MMWR Morb Mortal Wkly Rep. 2021;70(24):900.","DOI":"10.15585\/mmwr.mm7014e1"},{"issue":"18","key":"10.1016\/j.mayocp.2022.09.007_bib4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2021.5469","article-title":"The leading causes of death in the US for 2020","volume":"325","author":"Ahmad","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1378\/chest.14-0655","article-title":"Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort","volume":"147","author":"M\u00fcllerova","year":"2015","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice\u2013based population with chronic obstructive pulmonary disease","volume":"198","author":"Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.mayocp.2022.09.007_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006720","article-title":"The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study","volume":"4","author":"Schmidt","year":"2014","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.mayocp.2022.09.007_bib10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2017.03.009","article-title":"Prevention of prostate cancer morbidity and mortality: primary prevention and early detection","volume":"101","author":"Barry","year":"2017","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.mayocp.2022.09.007_bib12","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Biondi-Zoccai G, Abbate A, et\u00a0al. Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55. Published correction appears in BMJ. 2013;346:f596.","DOI":"10.1136\/bmj.f55"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.amepre.2010.12.017","article-title":"Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality","volume":"40","author":"Hoerger","year":"2011","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib14","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.09.007_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.23736\/S1973-9087.21.06279-1","article-title":"Long-term pulmonary rehabilitation progressively reduces hospitalizations and mortality in a cohort of patients with severe and very severe COPD: a 5-year follow up","volume":"57","author":"Reis","year":"2021","journal-title":"Eur J Phys Rehabil Med"},{"issue":"8222","key":"10.1016\/j.mayocp.2022.09.007_bib17","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party","volume":"1","year":"1981","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mayocp.2022.09.007_bib18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.rmed.2013.05.009","article-title":"Factors associated with changes in quality of life of COPD patients: a prospective study in primary care","volume":"107","author":"Monteagudo","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.mayocp.2022.09.007_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejcdt.2012.08.012","article-title":"Quality of life in COPD patients","volume":"61","author":"Zamzam","year":"2012","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12931-017-0548-3","article-title":"Understanding the impact of symptoms on the burden of COPD","volume":"18","author":"Miravitlles","year":"2017","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mayocp.2022.09.007_bib24","doi-asserted-by":"crossref","unstructured":"Nici L, Mammen MJ, Charbek E, et\u00a0al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56-e69. Published correction appears in Am J Respir Crit Care Med. 2020;202(6):910.","DOI":"10.1164\/rccm.202003-0625ST"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2022.09.007_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.mayocp.2022.09.007_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036455","article-title":"Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"10","author":"Axson","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.mayocp.2022.09.007_bib28","first-page":"785","article-title":"Dual therapy strategies for COPD: the scientific rationale for LAMA\u00a0+ LABA","volume":"11","author":"Cohen","year":"2016","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"10.1016\/j.mayocp.2022.09.007_bib29","doi-asserted-by":"crossref","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et\u00a0al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747-758. Published correction appears in Lancet Respir Med. 2018;6(11):e55 and Lancet Respir Med. 2019;7(2):e9.","DOI":"10.1016\/S2213-2600(18)30327-8"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.mayocp.2022.09.007_bib31","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2022.09.007_bib32","doi-asserted-by":"crossref","unstructured":"Mammen MJ, Lloyd DR, Kumar S, et\u00a0al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(10):1308-1318. Published correction appears in Ann Am Thorac Soc. 2021;18(2):377.","DOI":"10.1513\/AnnalsATS.202001-023OC"},{"key":"10.1016\/j.mayocp.2022.09.007_bib33","doi-asserted-by":"crossref","unstructured":"Papi A, Vestbo J, Fabbri L, et\u00a0al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076-1084. Published correction appears in Lancet. 2018;391(10125):1022.","DOI":"10.1016\/S0140-6736(18)30206-X"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10048","key":"10.1016\/j.mayocp.2022.09.007_bib35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.02.00301302","article-title":"Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice","volume":"20","author":"Soriano","year":"2002","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/15412555.2015.1044861","article-title":"The effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in Italy","volume":"13","author":"Di Martino","year":"2016","journal-title":"COPD"},{"issue":"8","key":"10.1016\/j.mayocp.2022.09.007_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.mayocp.2022.09.007_bib40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200906-0876OC","article-title":"Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease","volume":"180","author":"Celli","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"10030","key":"10.1016\/j.mayocp.2022.09.007_bib41","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2022.09.007_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01230-2018","article-title":"Inhaled corticosteroid containing combinations and mortality in COPD","volume":"52","author":"Vestbo","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.mayocp.2022.09.007_bib43","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.09.007_bib44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.09.007_bib45","doi-asserted-by":"crossref","first-page":"A1755","DOI":"10.1016\/j.chest.2020.08.1539","article-title":"Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate\u2013containing therapy: post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation","volume":"158","author":"Calverley","year":"2020","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.mayocp.2022.09.007_bib46","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.mayocp.2022.09.007_bib48","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/resp.13620","article-title":"Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD","volume":"24","author":"Reilev","year":"2019","journal-title":"Respirology"},{"issue":"160","key":"10.1016\/j.mayocp.2022.09.007_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib50","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1378\/chest.111.3.732","article-title":"Adverse effects of corticosteroid therapy for COPD. A critical review","volume":"111","author":"McEvoy","year":"1997","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mayocp.2022.09.007_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.chest.2017.08.027","article-title":"Inhaled corticosteroids and fractures in COPD: can we finally put this to bed?","volume":"153","author":"Cho","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mayocp.2022.09.007_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.chest.2017.07.002","article-title":"Long-term use of inhaled corticosteroids in COPD and the risk of fracture","volume":"153","author":"Gonzalez","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mayocp.2022.09.007_bib53","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00515-2020","article-title":"Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study","volume":"57","author":"Janson","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib54","first-page":"CD010115","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"2014","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.mayocp.2022.09.007_bib55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1513\/AnnalsATS.202002-096OC","article-title":"Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT","volume":"18","author":"Dransfield","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"10159","key":"10.1016\/j.mayocp.2022.09.007_bib56","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2022.09.007_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","article-title":"Number needed to treat (NNT) in clinical literature: an appraisal","volume":"15","author":"Mendes","year":"2017","journal-title":"BMC Med"},{"issue":"8934","key":"10.1016\/j.mayocp.2022.09.007_bib59","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"9326","key":"10.1016\/j.mayocp.2022.09.007_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2022.09.007_bib63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/COPD.S291967","article-title":"Benefit\/risk profile of single-inhaler triple therapy in COPD","volume":"16","author":"Bourbeau","year":"2021","journal-title":"Int J Chron Obstruct Pulm Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2022.09.007_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2214\/AJR.11.7146","article-title":"Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death","volume":"198","author":"Hendrick","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.mayocp.2022.09.007_bib61","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. Published correction appears in N Engl J Med. 2000;342(18):1376.","DOI":"10.1056\/NEJM200005043421819"},{"key":"10.1016\/j.mayocp.2022.09.007_bib62","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. Published correction appears in Lancet. 1998;352(9139):1558.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"issue":"6","key":"10.1016\/j.mayocp.2022.09.007_bib65","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1183\/09031936.00133805","article-title":"Mortality in COPD: role of comorbidities","volume":"28","author":"Sin","year":"2006","journal-title":"Eur Respir J"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622005420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622005420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:57:19Z","timestamp":1706003839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622005420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0025619622005420"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.09.007","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}